Subcutaneous immunoglobulin in polymyositis and dermatomyositis: A novel application

► IVIg has become a relevant treatment option in various immune-mediated diseases, including PM and DM. ► SCIg could act at different levels than IVIg in modulating the pathogenic immune response. ► The use of SCIg reduces the risk of adverse effects and the cost of IVIg treatment.